Cancer Institute A national cancer institute
designated cancer center

Multiple Myeloma

Myeloma bone disease is cancer that affects certain white blood cells called plasma cells. Plasma cells produce antibodies - proteins that help the body rid itself of harmful substances. When cancer occurs, the body overproduces abnormal plasma cells called myeloma cells.

Myeloma cells collect in the bone marrow and the hard outer part of the bone.

A Team Approach

The Stanford Cancer Center operates on a multidisciplinary approach that brings together a comprehensive, highly specialized team of board-certified physicians dedicated to tailoring special individualized treatment plans for each individual’s cancer. Backed by deep fundamental research and an extensive knowledge base in bone and blood cancer, our multidisciplinary team of experienced specialists in hematology, blood and marrow transplantation, radiology, interventional radiology, pathology, radiation oncology, medical oncology, and surgical oncology.

With all your doctors working together, you can be assured that all possible treatment approaches have been considered and the one that is best for you is put into place.

Stanford Expertise

When you are being treated for cancer you want a physician who is familiar with your particular disease. Yet because multiple myeloma is relatively rare it can be difficult to find a doctor who has treated patients with the disease.

Our specialists at the Cancer Center not only treat multiple myeloma, but have expertise managing complex cases, and offer the most advanced diagnostic technologies and treatments available today.

Combination chemotherapy that targets the myeloma cells is the main treatment for multiple myeloma and is delivered in the infusion center at the Cancer Center.

People who have multiple myeloma sometimes also receive radiation therapy that is designed to help control the growth of tumors in the bones and relieve the pain that these tumors cause.

Access to Experimental Therapies
Cancer Center physicians actively study new investigational therapies for patients with multiple myeloma. For example, our physicians participated in clinical trials for Velcade (bortezomib) a novel proteasome inhibitor, providing patients early access to this new treatment approach that is now FDA approved for the treatment of multiple myeloma.

Today, just some of the clinical trials that Cancer Center researchers and physicians can offer to multiple myeloma patients with advanced disease include:

Follow-up Care
Multiple myeloma is a disease that can advance slowly and often recurs. Therefore, regular follow-up care is extremely important for multiple myeloma patients. You can rely on your Cancer Center physician to conduct the exams and tests that will ensure early detection if your disease does progress.


Stanford Medicine Resources:

Footer Links: